Benign Prostatic Hyperplasia – Prostate Cancer – Prostatitis

Posts Tagged ‘Medroxyprogesterone’

Renal Cancer

No Comments
Renal cancer is a relatively rare cancer accounting for approximately 3% of all adult malignancies. There are more than 5000 new cases diagnosed per year in the UK and the incidence is increasing. It most commonly affects people in their fifth to seventh decades with a male-to-female ratio of approximately 2:1. Renal cell carcinoma (also known as clear cell carcinoma or hyper-nephroma) accounts for 80-85% of all kidney cancers. Papillary renal carcinoma constitutes approximately 10%, with the remainder including chromophobe and collecting duct carcinomas. Transitional cell carcinomas, squamous cell carcinomas and lymphomas can also arise in the kidney. Risk factors for the development of Renal cell carcinoma include smoking, obesity, adult polycystic kidney disease and long-term renal replacement therapy. Approximately 1% of RCCs are hereditary, the most commonly associated syndrome being the von Hippel-Lindau syndrome. It has recently been demonstrated that most cases of sporadic Renal cell carcinoma have mutations in the von Hippel-Lindau gene, located on the short arm of chromosome three, Read more [...]

Drugs available

No Comments
Interferons Interferons are a heterogeneous group of glycoproteins produced by mammalian cells in response to viral infections or other inducers. Three major types have been identified - interferon-a, interferon-β (class I) and inter-feron-8 (class II). As well as helping to fight viruses, interferons have anti-tumour properties. These may be mediated through a direct cytotoxic effect on tumour cells or through augmentation of the immunogenicity of tumours by upregulation of histocompatibility and tumour-associated antigens, and/ or activation of macrophages, T lymphocytes and natural killer cells [14]. It is also thought that interferons possess anti-angiogenic properties. The anti-neoplastic activity of IFN-a was first shown in hairy cell leukaemia and Kaposi's sarcoma. Subsequent studies have documented its activity in chronic mylogenous leukaemia, B and T cell lymphomas and melanoma. IFN-a is the most extensively tested IFN in clinical studies of patients with mRCC. The use of IFN-a in Renal cell carcinoma first began in the 1980s. It is now widely accepted in the UK as first-line Read more [...]

Leuprolide Acetate: Uses

No Comments
• Prostate Cancer Leuprolide acetate is used for the palliative treatment of advanced prostate cancer. The drug currently is considered alternative therapy for patients with inoperable prostatic tumors and/or who are intolerant to estrogen therapy (i.e., those at risk of estrogen-induced thromboembolic and thrombotic disorders, other cardiovascular effects, or other adverse effects) and for patients who refuse orchiectomy and/or estrogen therapy. Most clinical studies with the drug have been performed in patients with prostate cancer clinically diagnosed as stage D2 (i.e., tumor with metastases to distant lymph nodes, bone, and/or viscera). Responses to leuprolide therapy generally have been evaluated based on the criteria of the National Prostatic Cancer Project (NPCP). Leuprolide acetate injection and suspension have been shown to have comparable efficacy and safety in the treatment of advanced prostate cancer. Although direct comparison in clinical trials has not been performed, the safety and efficacy of the 4-month depot injection appear similar to the other leuprolide depot formulations. Read more [...]

Estramustine Phosphate Sodium

No Comments
C23H30ClNNaO6P • Estramustine phosphate sodium, a complex of 17 ?-estradiol and nornitrogen mustard, is an antimicrotubule antineoplastic agent. Uses • Prostate Cancer Estramustine phosphate sodium is used for the palliative treatment of metastatic and/or progressive prostate cancer. The drug, alone or in combination with other antineoplastic agents, currently is considered by many clinicians to be an alternative to conventional measures (e.g., orchiectomy, hormonal therapy) and generally is used in the treatment of hormone-refractory prostate cancer. Safety and efficacy of estramustine have been evaluated in controlled and uncontrolled studies in patients with advanced metastatic prostate cancer refractory to conventional measures (e.g., hormonal therapy) as well as in those with previously untreated disease. Most studies were conducted before the realization that administration of estramustine with milk or calcium-containing products substantially impairs absorption of the drug; therefore, overall clinical efficacy (i.e., objective response) of estramustine may have been underestimated. Read more [...]

Steroidal Antiandrogens

No Comments
Overview. Chronic administration of steroidal androgens can suppress adrenocortical function (i.e., interfere with the body's ability to regulate endogenous steroid production). These agents have been replaced by the nonsteroidal antiandrogens, which lack this complicating side effect. Mechanism Of Action. Steroidal antiandrogens prevent binding of testosterone and dihydrotestosterone (DHT) (androgens) to the androgen receptor within normal and cancerous prostate cells (Figure 2). In this way, they stop prostate cell growth. Steroidal antiandrogens have less antiandrogenic activity than nonsteroidal antiandrogens, but because they have a progestin-like effect on the pituitary, they can reduce the secretion of luteinizing hormone from the pituitary. As a result, steroidal antiandrogens can reduce testosterone secretion to levels similar to those achieved by castration. Cyproterone Acetate. Cyproterone acetate (Schering's Androcur / Cyprostat, Japan, enapharm's Androcur, generics) is marketed in France, Germany, and the United Kingdom for the treatment of CaP. It is approved for the suppression Read more [...]

Progesterone

No Comments
(British Approved Name, rINN) Drug Nomenclature International Nonproprietary Names (INNs) in main languages (French, Latin, Russian, and Spanish): Synonyms: Corpus Luteum Hormone; Luteal Hormone; Luteine; Luteohormone; NSC-9704; Pregnenedione; Progesteron; Progesterona; Progesteronas; Progesteroni; Progesteronum; Progeszteron BAN: Progesterone INN: Progesterone [rINN (en)] INN: Progesterona [rINN (es)] INN: Progestérone [rINN (fr)] INN: Progesteronum [rINN (la)] INN: Прогестерон [rINN (ru)] Chemical name: Pregn-4-ene-3,20-dione Molecular formula: C21H30O2 =314.5 CAS: 57-83-0 ATC code: G03DA04 Read code: y07kn; y07ko Pharmacopoeias. In China, Europe, International, Japan, US. European Pharmacopoeia, 6th ed. (Progesterone). Awhite or almost white crystalline powder or colourless crystals. It exhibits polymorphism. Practically insoluble in water freely soluble in dehydrated alcohol sparingly soluble in acetone and in fatty oils. Protect from light. The United States Pharmacopeia 31, 2008 (Progesterone). A white or creamy-white, odourless, crystalline powder. Practically Read more [...]

Megestrol Acetate

No Comments
Drug Approvals (BANM, US Adopted Name, rINNM) Synonyms: BDH-1298; Compound 5071; Megestrol, acetato de; Megestrol-acetát; Megestrolacetat; Megestroli Acetas; Megestroliasetaatti; Megestrolio acetatas; Megesztrol-acetát; NSC-71423; SC-10363 BAN: Megestrol Acetate [BANM] USAN: Megestrol Acetate INN: Megestrol Acetate [rINNM (en)] INN: Acetato de megestrol [rINNM (es)] INN: Mégestrol, Acétate de [rINNM (fr)] INN: Megestroli Acetas [rINNM (la)] INN: Мегестрола Ацетат [rINNM (ru)] Chemical name: 6-Methyl-3,20-dioxopregna-4,6-dien-17α-yl acetate; 17α-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate Molecular formula: C24H32O4 =384.5 CAS: 3562-63-8 (megestrol); 595-33-5 (megestrol acetate) ATC code: G03AC05; G03DB02; L02AB01 Read code: y02oH Pharmacopoeias. In China, Europe, and US. European Pharmacopoeia, 6th ed. (Megestrol Acetate). A white or almost white crystalline powder. Practically insoluble in water sparingly soluble in alcohol soluble in acetone. Protect from light. The United States Pharmacopeia 31, 2008 (Megestrol Acetate). A white to creamy-white, Read more [...]

Aminoglutethimide

No Comments
(British Approved Name, rINN) Drug Nomenclature International Nonproprietary Names (INNs) in main languages (French, Latin, Russian, and Spanish): Synonyms: Aminoglutethimid; Aminoglutethimidum; Aminoglutetimid; Aminoglutetimida; Aminoglutetimidas; Aminoglutetimidi; Ba-16038 BAN: Aminoglutethimide INN: Aminoglutethimide [rINN (en)] INN: Aminoglutetimida [rINN (es)] INN: Aminoglutéthimide [rINN (fr)] INN: Aminoglutethimidum [rINN (la)] INN: Аминоглутетимид [rINN (ru)] Chemical name: 2-(4-Aminophenyl)-2-ethylglutarimide; 3-(4-Aminophenyl)-3-ethylpiperidine-2,6-dione Molecular formula: C13H16N2O2 =232.3 CAS: 125-84-8 ATC code: L02BG01 Read code: y02oN Pharmacopoeias. In China, Europe, and US. European Pharmacopoeia, 6th ed., 2008 and Supplements 6.1 and 6.2 (Aminoglutethimide). A white or slightly yellow, crystalline powder. Practically insoluble in water; freely soluble in acetone; soluble in methyl alcohol. The United States Pharmacopeia 31, 2008 (Aminoglutethimide). A white or creamy-white, fine, crystalline powder. Very slightly soluble in water; readily Read more [...]